6LJ0 Stock Overview A clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Matinas BioPharma Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Matinas BioPharma Holdings Historical stock prices Current Share Price US$2.69 52 Week High US$20.75 52 Week Low US$1.45 Beta 1.73 1 Month Change 0% 3 Month Change -13.50% 1 Year Change -66.99% 3 Year Change -94.34% 5 Year Change -95.11% Change since IPO -98.20%
Recent News & Updates
Matinas BioPharma Holdings, Inc. Announces Executive Changes Oct 25
Matinas BioPharma Holdings, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 07
Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program Jun 25
New major risk - Revenue and earnings growth May 12 Matinas BioPharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024
New minor risk - Shareholder dilution Apr 07 See more updates
Matinas BioPharma Holdings, Inc. Announces Executive Changes Oct 25
Matinas BioPharma Holdings, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 07
Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program Jun 25
New major risk - Revenue and earnings growth May 12 Matinas BioPharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024
New minor risk - Shareholder dilution Apr 07 Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Apr 05
Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Apr 04
Full year 2023 earnings released: US$0.11 loss per share (vs US$0.097 loss in FY 2022) Mar 28
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation Mar 27
Matinas BioPharma Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 26
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards Mar 25
Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution Feb 28
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis Feb 20
Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides Dec 28
Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA Dec 22
Third quarter 2023 earnings released: US$0.028 loss per share (vs US$0.025 loss in 3Q 2022) Nov 10
Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model Nov 08
Matinas BioPharma Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 02
Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient’s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203 Oct 12
No longer forecast to breakeven Oct 06
Insufficient new directors Oct 01
Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC Sep 24
Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC Sep 23
Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023 Sep 20
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases Aug 23
Matinas BioPharma Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
Matinas BioPharma Holdings, Inc. to Report Q1, 2023 Results on May 10, 2023 May 04
Full year 2022 earnings released: US$0.097 loss per share (vs US$0.11 loss in FY 2021) Mar 17
Forecast to breakeven in 2025 Dec 31
Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.032 loss in 3Q 2021) Nov 04
Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90% Oct 22
Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022 Sep 23
Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022 Sep 22
Second quarter 2022 earnings released: US$0.027 loss per share (vs US$0.024 loss in 2Q 2021) Aug 12
Insufficient new directors Apr 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 09
No longer forecast to breakeven Mar 08
Insufficient new directors Jan 02
Forecast to breakeven in 2024 Jan 01
Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final Cohort of Patients in the Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis Dec 17
Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold Sep 14
Forecast to breakeven in 2025 May 15
Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa® Feb 02
Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001 Jan 05
New 90-day high: €1.37 Jan 04
Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology Dec 10
Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer Dec 02
New 90-day high: €0.84 Nov 28
Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients Nov 21
Revenue beats expectations Nov 07
Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis Oct 20
New 90-day low - €0.61 Sep 08
Earnings released Aug 11
New 90-day high - €0.85 Jul 24 Shareholder Returns 6LJ0 DE Biotechs DE Market 7D 0% 5.8% 2.0% 1Y -67.0% -6.1% 9.6%
See full shareholder returns
Return vs Market: 6LJ0 underperformed the German Market which returned 8.5% over the past year.
Price Volatility Is 6LJ0's price volatile compared to industry and market? 6LJ0 volatility 6LJ0 Average Weekly Movement n/a Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6LJ0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6LJ0's volatility change over the past year.
About the Company Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.
Show more Matinas BioPharma Holdings, Inc. Fundamentals Summary How do Matinas BioPharma Holdings's earnings and revenue compare to its market cap? 6LJ0 fundamental statistics Market cap €2.94m Earnings (TTM ) -€20.13m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6LJ0 income statement (TTM ) Revenue US$0 Cost of Revenue US$14.49m Gross Profit -US$14.49m Other Expenses US$6.64m Earnings -US$21.13m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/25 07:41 End of Day Share Price 2024/08/28 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Matinas BioPharma Holdings, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Scott Henry Alliance Global Partners Jason McCarthy Maxim Group Yasmeen Rahimi Piper Sandler Companies
Show 2 more analysts 
